Corporate Presentation June 2025 Forward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, statements regarding, among other things, the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr generally; the potential regulatory path forward for tebipenem HBr, the potential approval of tebipenem HBr by the U.S. Food and Drug Admini ...

Key Takeaways AstraZeneca gained EU approval for Imfinzi to treat muscle-invasive bladder cancer in adults. Imfinzi showed a 32% reduced risk of disease progression or death in the NIAGARA phase III study. Imfinzi sales rose 16% in Q1 2025 to $1.26B, driven by lung and liver cancer treatment demand.AstraZeneca (AZN) announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a bladder cancer indication in the European Union (EU).The regulatory body in Europe ...

Key Takeaways VRTX gains EU approval for Alyftrek to treat CF patients aged six and above with non-class I mutations. Alyftrek offers once-daily dosing and potential benefits over Trikafta, including improved CFTR function. Alyftrek sales reached $53.9M in Q1 2025, with management expecting stronger uptake in H2 2025.Vertex Pharmaceuticals (VRTX) announced that the European Commission has approved Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for treating people with cystic fibrosis (“CF”) aged six year ...

Key Takeaways RCKT received FDA clearance to start clinical trials for its gene therapy candidate RP-A701. The phase I study will assess RP-A701's safety, biological activity and preliminary efficacy. Participants will receive a single RP-A701 dose, with multiple cardiac health markers being monitored.Rocket Pharmaceuticals (RCKT) announced that the FDA has cleared its investigational new drug (IND) application seeking to begin clinical studies on its first-in-class gene therapy candidate, RP-A701.The com ...

Key Takeaways AbbVie is acquiring Capstan Therapeutics for up to $2.1B to expand its immunology portfolio. The acquisition adds CPTX2309, a phase I in vivo CAR-T therapy for autoimmune diseases, to AbbVie's pipeline. Capstan's CellSeeker tLNP platform enables RNA delivery to engineer specific cell types inside the body.AbbVie (ABBV) announced that it has entered into a definitive agreement to acquire privately held biotech, Capstan Therapeutics, for up to $2.1 billion in cash.The impending acquisition wil ...

Key Takeaways The VOR stock surged after licensing ex-China rights to telitacicept from RemeGen. The licensing deal totals $125M upfront and stock, plus more than $4B in potential milestones and royalties. VOR appoints Jean-Paul Kress as its new chief executive officer and chairman of the board.Shares of Vor Bio (VOR) have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, the company entered a licensing agreement with RemeGen, a China-based pharmaceutical co ...

Following the recommendation of the IDMC, Spero Therapeutics (NASDAQ: SPRO ) has decided to stop its PIVOT-PO Phase 3 trial early and ahead of schedule. The study's objective of non-inferiority to intravenous imipenem-cilastatin was achieved , although theHey there, I would like to encourage you to follow me and read my articles for stocks with an excellent risk-reward profile. i am an individual who enjoys dealing with public Biotech companys. I write articles not for investment activities, I just want to ...

点击蓝字，关注我们 今日上午港股 1、众安在线(06060)再涨超8% ，月内累涨超50%，稳定币法案显著利好众安银行虚拟资产业务； 2、教育股集体上涨 ，中教控股(0839)涨超5%，新东方(9901)涨超2%； 3、金山软件(03888)大跌超6% ，Q1营收低于预期 4、出口股走强 ，申洲国际(02313)早盘涨近5%暂时领涨蓝筹，美联邦法院阻止特朗普关税政策生效 5、黄金股集体走低 ，国际金价下跌向下触及3250美元 7、君实生物(01877)再涨超6% ，君适达新增两项适应症获批 公司加速推进在研管线临床进度 6、苹果概念股齐涨 ，美国法院叫停特朗普关税，瑞声科技(02018)、丘钛科技（01478）、舜宇光学 (02382)涨超2%，伟仕佳杰(00856)、高伟电子(01415)跟涨； 9、泡泡玛特(09992)涨超4% ，Labubu3.0引发全球现象级热潮，饰品品牌POPOP将开首家正式门店； 10、CRO概念股走强 ，药明生物涨超8%，药明康德、昭衍新药涨超4%。美国国际贸易法院"叫停"特 朗普政府一揽子关税，前期受损标的迎来反弹； 11、鸿腾精密(06088)盘中涨超6% ，英伟达数据中心 ...

Company Performance - Spero Therapeutics reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.55, representing an earnings surprise of 54.55% [1] - The company posted revenues of $5.87 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 46.60%, compared to revenues of $9.27 million a year ago [2] - Over the last four quarters, Spero Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Outlook - Spero Therapeutics shares have declined approximately 40.8% since the beginning of the year, while the S&P 500 has only declined by 0.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.32 on $11 million in revenues, and for the current fiscal year, it is -$2.32 on $60 million in revenues [7] - The estimate revisions trend for Spero Therapeutics is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Spero Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Spero Therapeutics' stock performance [5]

Exhibit 99.1 Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update CAMBRIDGE, Mass., May 13, 2025 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. "At Spero, our top priority remains the successf ...